Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 995

1.

Aortic regurgitation, a forgotten valve disease in hypertrophic cardiomyopathy?

Westenbrink BD, de Boer RA, Vliegenthart R.

Eur J Radiol. 2020 Mar 19;126:108971. doi: 10.1016/j.ejrad.2020.108971. [Epub ahead of print] No abstract available.

PMID:
32247164
2.

Sex-related differences in contemporary biomarkers for heart failure: a review.

Suthahar N, Meems LMG, Ho JE, de Boer RA.

Eur J Heart Fail. 2020 Mar 27. doi: 10.1002/ejhf.1771. [Epub ahead of print] Review.

PMID:
32220046
3.

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.

Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett J, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Vinh PN, Schou M, Tereshchenko S, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD, Johanson P, Greasley PJ, Boulton D, Bengtsson O, Jhund PS, McMurray JJV.

JAMA. 2020 Mar 27. doi: 10.1001/jama.2020.1906. [Epub ahead of print]

PMID:
32219386
4.

Custom DNA microarrays reveal diverse binding preferences of proteins and small molecules to thousands of G-quadruplexes.

Ray S, Tillo D, Boer RE, Assad N, Barshai M, Wu G, Orenstein Y, Yang D, Schneekloth JS Jr, Vinson C.

ACS Chem Biol. 2020 Mar 27. doi: 10.1021/acschembio.9b00934. [Epub ahead of print]

PMID:
32216326
5.

Chemical Modulation of Pre-mRNA Splicing in Mammalian Systems.

Boer RE, Torrey ZR, Schneekloth JS Jr.

ACS Chem Biol. 2020 Mar 19. doi: 10.1021/acschembio.0c00001. [Epub ahead of print]

PMID:
32191432
6.

The naive T-cell receptor repertoire has an extremely broad distribution of clone sizes.

de Greef PC, Oakes T, Gerritsen B, Ismail M, Heather JM, Hermsen R, Chain B, de Boer RJ.

Elife. 2020 Mar 18;9. pii: e49900. doi: 10.7554/eLife.49900.

7.

Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction.

Yurista SR, Silljé HHW, van Goor H, Hillebrands JL, Heerspink HJL, de Menezes Montenegro L, Oberdorf-Maass SU, de Boer RA, Westenbrink BD.

Cardiovasc Drugs Ther. 2020 Mar 17. doi: 10.1007/s10557-020-06954-6. [Epub ahead of print]

PMID:
32185580
8.

Is T Cell Negative Selection a Learning Algorithm?

Wortel IMN, Keşmir C, de Boer RJ, Mandl JN, Textor J.

Cells. 2020 Mar 11;9(3). pii: E690. doi: 10.3390/cells9030690.

9.

How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G.

Eur J Heart Fail. 2020 Mar;22(3):391-412. doi: 10.1002/ejhf.1741. Epub 2020 Mar 5.

PMID:
32133741
10.

Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozin vs placebo or empagliflozin in patients with type 2 diabetes and heart failure.

de Boer RA, Núñez J, Kozlovski P, Wang Y, Proot P, Keefe D.

Br J Clin Pharmacol. 2020 Feb 18. doi: 10.1111/bcp.14248. [Epub ahead of print]

PMID:
32068914
11.

Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes.

Iborra-Egea O, Santiago-Vacas E, Yurista SR, Lupón J, Packer M, Heymans S, Zannad F, Butler J, Pascual-Figal D, Lax A, Núñez J, de Boer RA, Bayés-Genís A.

JACC Basic Transl Sci. 2019 Oct 23;4(7):831-840. doi: 10.1016/j.jacbts.2019.07.010. eCollection 2019 Nov.

12.

Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling.

Hofland T, Endstra S, Gomes CKP, de Boer R, de Weerdt I, Bobkov V, Riedl JA, Heukers R, Smit MJ, Eldering E, Levin MD, Kater AP, Tonino SH.

Hemasphere. 2019 Oct 30;3(6):e308. doi: 10.1097/HS9.0000000000000308. eCollection 2019 Dec.

13.

Reverse Cardio-Oncology: Cancer Development in Patients With Cardiovascular Disease.

Aboumsallem JP, Moslehi J, de Boer RA.

J Am Heart Assoc. 2020 Jan 21;9(2):e013754. doi: 10.1161/JAHA.119.013754. Epub 2020 Jan 21. No abstract available.

14.

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial.

Mansfield AS, Każarnowicz A, Karaseva N, Sánchez A, De Boer R, Andric Z, Reck M, Atagi S, Lee JS, Garassino M, Liu SV, Horn L, Wen X, Quach C, Yu W, Kabbinavar F, Lam S, Morris S, Califano R.

Ann Oncol. 2020 Feb;31(2):310-317. doi: 10.1016/j.annonc.2019.10.021. Epub 2019 Dec 9.

15.

ATF2 and ATF7 Are Critical Mediators of Intestinal Epithelial Repair.

Meijer BJ, Giugliano FP, Baan B, van der Meer JHM, Meisner S, van Roest M, Koelink PJ, de Boer RJ, Jones N, Breitwieser W, van der Wel NN, Wildenberg ME, van den Brink GR, Heijmans J, Muncan V.

Cell Mol Gastroenterol Hepatol. 2020 Jan 17. pii: S2352-345X(20)30005-9. doi: 10.1016/j.jcmgh.2020.01.005. [Epub ahead of print]

16.

Troponins and natriuretic peptides to detect cardiotoxicity: useful biomarkers or paradise lost?

Bracun V, de Boer RA.

Eur J Heart Fail. 2020 Feb;22(2):362-365. doi: 10.1002/ejhf.1676. Epub 2020 Jan 16. No abstract available.

PMID:
31944511
17.

Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T.

Aimo A, Januzzi JL Jr, Vergaro G, Richards AM, Lam CSP, Latini R, Anand IS, Cohn JN, Ueland T, Gullestad L, Aukrust P, Brunner-La Rocca HP, Bayes-Genis A, Lupón J, de Boer RA, Takeishi Y, Egstrup M, Gustafsson I, Gaggin HK, Eggers KM, Huber K, Gamble GD, Ling LH, Leong KTG, Yeo PSD, Ong HY, Jaufeerally F, Ng TP, Troughton R, Doughty RN, Passino C, Emdin M.

Eur J Heart Fail. 2020 Jan 9. doi: 10.1002/ejhf.1701. [Epub ahead of print]

PMID:
31919929
18.

Time to Viral Suppression in Perinatally HIV-Infected Infants Depends on the Viral Load and CD4 T-Cell Percentage at the Start of Treatment.

Schröter J, Anelone AJN, Yates AJ, de Boer RJ; EPIICAL Consortium.

J Acquir Immune Defic Syndr. 2020 Apr 15;83(5):522-529. doi: 10.1097/QAI.0000000000002291.

PMID:
31917752
19.

Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?

Yurista SR, Silljé HHW, Rienstra M, de Boer RA, Westenbrink BD.

Cardiovasc Diabetol. 2020 Jan 7;19(1):5. doi: 10.1186/s12933-019-0984-0.

20.

Recent advances in cardio-oncology: a report from the 'Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019'.

Anker MS, Hadzibegovic S, Lena A, Belenkov Y, Bergler-Klein J, de Boer RA, Farmakis D, von Haehling S, Iakobishvili Z, Maack C, Pudil R, Skouri H, Cohen-Solal A, Tocchetti CG, Coats AJS, Seferović PM, Lyon AR; Heart Failure Association Cardio-Oncology Study Group of the European Society of Cardiology.

ESC Heart Fail. 2019 Dec;6(6):1140-1148. doi: 10.1002/ehf2.12551. Epub 2019 Dec 28.

21.

Mitochondrial therapy for Doxorubicin cardiomyopathy: NF-κB to the rescue?

Nijholt KT, Westenbrink BD, de Boer RA.

Cardiovasc Res. 2019 Dec 23. pii: cvz344. doi: 10.1093/cvr/cvz344. [Epub ahead of print] No abstract available.

PMID:
31868877
22.

Improve Management of acute heart failure with ProcAlCiTonin in EUrope: results of the randomized clinical trial IMPACT EU Biomarkers in Cardiology (BIC) 18.

Möckel M, de Boer RA, Slagman AC, von Haehling S, Schou M, Vollert JO, Wiemer JC, Ebmeyer S, Martín-Sánchez FJ, Maisel AS, Giannitsis E.

Eur J Heart Fail. 2020 Feb;22(2):267-275. doi: 10.1002/ejhf.1667. Epub 2019 Dec 12.

PMID:
31833168
23.

Pharmacological myeloperoxidase (MPO) inhibition in an obese/hypertensive mouse model attenuates obesity and liver damage, but not cardiac remodeling.

Piek A, Koonen DPY, Schouten EM, Lindtstedt EL, Michaëlsson E, de Boer RA, Silljé HHW.

Sci Rep. 2019 Dec 10;9(1):18765. doi: 10.1038/s41598-019-55263-y.

24.

Incidence, clinical implications and impact on public health of infections with Shigella spp. and entero-invasive Escherichia coli (EIEC): results of a multicenter cross-sectional study in the Netherlands during 2016-2017.

van den Beld MJC, Warmelink E, Friedrich AW, Reubsaet FAG, Schipper M, de Boer RF, Notermans DW, Petrignani MWF, van Zanten E, Rossen JWA, Friesema IHM, Kooistra-Smid AMDM; IBESS working group.

BMC Infect Dis. 2019 Dec 9;19(1):1037. doi: 10.1186/s12879-019-4659-y.

25.

European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.

Seferović PM, Coats AJS, Ponikowski P, Filippatos G, Huelsmann M, Jhund PS, Polovina MM, Komajda M, Seferović J, Sari I, Cosentino F, Ambrosio G, Metra M, Piepoli M, Chioncel O, Lund LH, Thum T, De Boer RA, Mullens W, Lopatin Y, Volterrani M, Hill L, Bauersachs J, Lyon A, Petrie MC, Anker S, Rosano GMC.

Eur J Heart Fail. 2020 Feb;22(2):196-213. doi: 10.1002/ejhf.1673. Epub 2019 Dec 9.

PMID:
31816162
26.

Characterization of the ferret TRB locus guided by V, D, J, and C gene expression analysis.

Gerritsen B, Pandit A, Zaaraoui-Boutahar F, van den Hout MCGN, van IJcken WFJ, de Boer RJ, Andeweg AC.

Immunogenetics. 2020 Feb;72(1-2):101-108. doi: 10.1007/s00251-019-01142-9. Epub 2019 Dec 3. Review.

27.

A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure : Design and rationale of the MONITOR HF multicentre randomised clinical trial.

Brugts JJ, Veenis JF, Radhoe SP, Linssen GCM, van Gent M, Borleffs CJW, van Ramshorst J, van Pol P, Tukkie R, Spee RF, Emans ME, Kok W, van Halm V, Handoko L, Beeres SLMA, Post MC, Boersma E, Lenzen MJ, Manintveld OC, Koffijberg H, van Baal P, Versteegh M, Smilde TD, van Heerebeek L, Rienstra M, Mosterd A, Delnoy PPH, Asselbergs FW, Brunner-La Rocca HP, de Boer RA.

Neth Heart J. 2020 Jan;28(1):16-26. doi: 10.1007/s12471-019-01341-9.

28.

Mapping actionable pathways and mutations in brain tumours using targeted RNA next generation sequencing.

Lenting K, van den Heuvel CNAM, van Ewijk A, ElMelik D, de Boer R, Tindall E, Wei G, Kusters B, Te Dorsthorst M, Ter Laan M, Huynen MA, Leenders WP.

Acta Neuropathol Commun. 2019 Nov 20;7(1):185. doi: 10.1186/s40478-019-0826-z.

29.

Specific IgE as the best predictor of the outcome of challenges to baked milk and baked egg.

De Boer R, Cartledge N, Lazenby S, Tobias A, Chan S, Fox AT, Santos AF.

J Allergy Clin Immunol Pract. 2019 Nov 11. pii: S2213-2198(19)30931-6. doi: 10.1016/j.jaip.2019.10.039. [Epub ahead of print] No abstract available.

30.

Hansenula polymorpha Pex37 is a peroxisomal membrane protein required for organelle fission and segregation.

Singh R, Manivannan S, Krikken AM, de Boer R, Bordin N, Devos DP, van der Klei IJ.

FEBS J. 2019 Nov 6. doi: 10.1111/febs.15123. [Epub ahead of print]

PMID:
31692262
31.

Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial.

Rachwan RJ, Butler J, Collins SP, Cotter G, Davison BA, Senger S, Ezekowitz JA, Filippatos G, Levy PD, Metra M, Ponikowski P, Teerlink JR, Voors AA, de Boer RA, Soergel DG, Felker GM, Pang PS.

Eur J Heart Fail. 2019 Dec;21(12):1561-1570. doi: 10.1002/ejhf.1607. Epub 2019 Oct 23.

PMID:
31646707
32.

Current understanding of fibrosis in genetic cardiomyopathies.

Eijgenraam TR, Silljé HHW, de Boer RA.

Trends Cardiovasc Med. 2019 Sep 23. pii: S1050-1738(19)30132-X. doi: 10.1016/j.tcm.2019.09.003. [Epub ahead of print] Review.

33.

Biocompatible and Biodegradable Magnesium Oxide Nanoparticles with In Vitro Photostable Near-Infrared Emission: Short-Term Fluorescent Markers.

Khalid A, Norello R, N Abraham A, Tetienne JP, J Karle T, W C Lui E, Xia K, A Tran P, J O'Connor A, G Mann B, de Boer R, He Y, Man Ching Ng A, B Djurisic A, Shukla R, Tomljenovic-Hanic S.

Nanomaterials (Basel). 2019 Sep 23;9(10). pii: E1360. doi: 10.3390/nano9101360.

34.

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Bělohlávek J, Böhm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde AM; DAPA-HF Trial Committees and Investigators.

N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.

PMID:
31535829
35.

Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes.

Hofland T, de Weerdt I, Ter Burg H, de Boer R, Tannheimer S, Tonino SH, Kater AP, Eldering E.

J Immunol. 2019 Oct 15;203(8):2100-2109. doi: 10.4049/jimmunol.1900321. Epub 2019 Sep 11.

PMID:
31511358
36.

HNRNPH1-dependent splicing of a fusion oncogene reveals a targetable RNA G-quadruplex interaction.

Neckles C, Boer RE, Aboreden N, Cross AM, Walker RL, Kim BH, Kim S, Schneekloth JS Jr, Caplen NJ.

RNA. 2019 Dec;25(12):1731-1750. doi: 10.1261/rna.072454.119. Epub 2019 Sep 11.

37.

Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.

de Weerdt I, Hofland T, de Boer R, Dobber JA, Dubois J, van Nieuwenhuize D, Mobasher M, de Boer F, Hoogendoorn M, Velders GA, van der Klift M, Remmerswaal EBM, Bemelman FJ, Niemann CU, Kersting S, Levin MD, Eldering E, Tonino SH, Kater AP.

Blood Adv. 2019 Sep 10;3(17):2642-2652. doi: 10.1182/bloodadvances.2019000360.

38.

How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G.

Eur Heart J. 2019 Oct 21;40(40):3297-3317. doi: 10.1093/eurheartj/ehz641.

PMID:
31504452
39.

A retrospective overview of International Collegiate programming contest data.

de Boer RH, de Campos CP.

Data Brief. 2019 Aug 12;25:104382. doi: 10.1016/j.dib.2019.104382. eCollection 2019 Aug.

40.

Toxin production spontaneously becomes regulated by local cell density in evolving bacterial populations.

Doekes HM, de Boer RJ, Hermsen R.

PLoS Comput Biol. 2019 Aug 30;15(8):e1007333. doi: 10.1371/journal.pcbi.1007333. eCollection 2019 Aug.

41.

World Heart Federation Roadmap for Heart Failure.

Ferreira JP, Kraus S, Mitchell S, Perel P, Piñeiro D, Chioncel O, Colque R, de Boer RA, Gomez-Mesa JE, Grancelli H, Lam CSP, Martinez-Rubio A, McMurray JJV, Mebazaa A, Panjrath G, Piña IL, Sani M, Sim D, Walsh M, Yancy C, Zannad F, Sliwa K.

Glob Heart. 2019 Sep;14(3):197-214. doi: 10.1016/j.gheart.2019.07.004. Review. No abstract available.

PMID:
31451235
42.

The association of multimorbidity within cardio-metabolic disease domains with dietary patterns: A cross-sectional study in 129 369 men and women from the Lifelines cohort.

Dekker LH, de Borst MH, Meems LMG, de Boer RA, Bakker SJL, Navis GJ.

PLoS One. 2019 Aug 8;14(8):e0220368. doi: 10.1371/journal.pone.0220368. eCollection 2019.

43.
44.

Cancer and heart disease: associations and relations.

de Boer RA, Meijers WC, van der Meer P, van Veldhuisen DJ.

Eur J Heart Fail. 2019 Dec;21(12):1515-1525. doi: 10.1002/ejhf.1539. Epub 2019 Jul 18.

45.

Amino Acid Loss during Continuous Venovenous Hemofiltration in Critically Ill Patients.

Stapel SN, de Boer RJ, Thoral PJ, Vervloet MG, Girbes ARJ, Oudemans-van Straaten HM.

Blood Purif. 2019;48(4):321-329. doi: 10.1159/000500998. Epub 2019 Jul 10.

46.

The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure.

Santema BT, Chan MMY, Tromp J, Dokter M, van der Wal HH, Emmens JE, Takens J, Samani NJ, Ng LL, Lang CC, van der Meer P, Ter Maaten JM, Damman K, Dickstein K, Cleland JG, Zannad F, Anker SD, Metra M, van der Harst P, de Boer RA, van Veldhuisen DJ, Rienstra M, Lam CSP, Voors AA.

Clin Res Cardiol. 2020 Mar;109(3):331-338. doi: 10.1007/s00392-019-01513-y. Epub 2019 Jul 1.

47.

Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens.

Cadeddu Dessalvi C, Pepe A, Penna C, Gimelli A, Madonna R, Mele D, Monte I, Novo G, Nugara C, Zito C, Moslehi JJ, de Boer RA, Lyon AR, Tocchetti CG, Mercuro G.

Heart Fail Rev. 2019 Nov;24(6):915-925. doi: 10.1007/s10741-019-09820-2. Review.

PMID:
31256318
48.

Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy.

Bauersachs J, König T, van der Meer P, Petrie MC, Hilfiker-Kleiner D, Mbakwem A, Hamdan R, Jackson AM, Forsyth P, de Boer RA, Mueller C, Lyon AR, Lund LH, Piepoli MF, Heymans S, Chioncel O, Anker SD, Ponikowski P, Seferovic PM, Johnson MR, Mebazaa A, Sliwa K.

Eur J Heart Fail. 2019 Jul;21(7):827-843. doi: 10.1002/ejhf.1493. Epub 2019 Jun 27.

PMID:
31243866
49.

Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations.

Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, Coats AJS, Metra M, Mebazaa A, Ruschitzka F, Lainscak M, Filippatos G, Seferovic PM, Meijers WC, Bayes-Genis A, Mueller T, Richards M, Januzzi JL Jr; Heart Failure Association of the European Society of Cardiology.

Eur J Heart Fail. 2019 Jun;21(6):715-731. doi: 10.1002/ejhf.1494.

PMID:
31222929
50.

Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome.

Aimo A, Januzzi JL Jr, Vergaro G, Clerico A, Latini R, Meessen J, Anand IS, Cohn JN, Gravning J, Ueland T, Nymo SH, Brunner-La Rocca HP, Bayes-Genis A, Lupón J, de Boer RA, Yoshihisa A, Takeishi Y, Egstrup M, Gustafsson I, Gaggin HK, Eggers KM, Huber K, Tentzeris I, Ripoli A, Passino C, Emdin M.

Eur J Prev Cardiol. 2019 Nov;26(16):1751-1759. doi: 10.1177/2047487319852809. Epub 2019 Jun 1.

PMID:
31154828

Supplemental Content

Support Center